LONDON, April 19,
2023 /PRNewswire/ -- Virax Biolabs Group Limited
("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotech
company focused on the detection of immune responses to and
diagnosis of viral diseases, announced today that it has entered
into an agreement for the distribution of Marburg Virus PCR testing
kits.
The Marburg Virus Real Time PCR Kit is an in-vitro diagnostic
test, based on real-time PCR technology, for the detection of
ribonucleic acid (better known as RNA) from the Marburg Virus. The
Company intends to launch the kit into areas accepting a CE
mark.
Virax's Chairman of the Board and Chief Executive
Officer, James Foster commented, "We are committed to
developing and distributing innovative diagnostic tools to combat
infectious diseases. Our Marburg Virus PCR testing kit is a
significant step forward in our mission to improve global
health."
The Marburg Virus Disease is a highly virulent disease which
causes hemorrhagic fever and requires assessment under the
International Health Regulations by the World Health Organization.
Given the severity of the disease, the use of accurate and reliable
test kits is critical to ensure the best possible outcomes for
individuals affected by the disease, as well as for safeguarding
public health more broadly.
About Virax Biolabs Group Limited
Founded in 2013, Virax Biolabs Group Limited is an innovative
biotech company focused on the detection of immune responses to and
diagnosis of viral diseases.
In addition to distributing an array of in-vitro diagnostic test
kits, Virax Biolabs Group Limited is currently developing a
proprietary T-Cell Test technology with the intention of providing
an immunology profiling platform that assesses each individual's
immune risk profile against major global viral threats. T-Cell
testing can be particularly effective in the diagnosis and
therapeutics of COVID-19 as well as other threats including
Monkeypox, Hepatitis B, Malaria, Herpes and Human
Papillomavirus.
For more information, please
visit www.viraxbiolabs.com.
Safe Harbor Statement
This press release contains forward-looking statements. In
addition, from time to time, we or our representatives may make
forward-looking statements orally or in writing. We base these
forward-looking statements on our expectations and projections
about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future
events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings;
and our business prospects and opportunities. You can identify
forward-looking statements by those that are not historical in
nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various
factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time
to time by us or our representatives, may not occur, and actual
events and results may differ materially and are subject to risks,
uncertainties, and assumptions about us. These forward-looking
statements are based on information currently available to Virax
and its current plans or expectations and are subject to a number
of known and unknown uncertainties, risks and other important
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. These and other important factors are
described in detail in the "Risk Factors" section of Virax's Annual
Report on Form 20-F for the year ended March
31, 2022. Although we believe the expectations reflected in
such forward-looking statements are reasonable, we can give no
assurance that such expectations will prove to be correct. We are
not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-group-limited-has-entered-into-an-agreement-for-the-distribution-of-marburg-virus-pcr-testing-kits-301801695.html
SOURCE Virax Biolabs